Hjem › Crohns sykdom › Ohio
Kliniske studier for Crohns sykdom i Ohio
30 studier for Crohns sykdom søker deltakere på steder i Ohio.
Byer i Ohio
Offisiell studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Great Lakes Gastroenterology Research, LLC ( Site 5016), Mentor
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07697456Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease
- UH Minoff Health Center, Chagrin Falls
- University Hospitals Cleveland Medical Center, Cleveland
- UH Westlake Health Center, Westlake
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 til 75 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07852273A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastro Health Research - Cincinnati, Cincinnati
- DSI Research Northridge LLC, Dayton
- Gastro Health Research - Liberty Township, Liberty Township
- og 3 flere
RekruttererFase 4
Alder 18 til 80 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06581328Non-nutritive Sweeteners in Inflammatory Bowel Disease
- UH Minoff Health Center, Chagrin Falls
- University Hospitals Cleveland Medical Center, Cleveland
- UH Westlake Health Center, Westlake
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 til 70 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07769437Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Cincinnati /ID# 265589, Cincinnati
- The Ohio State University /ID# 265577, Columbus
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07499232A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererFase 3
Alder 3 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06663332A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
RekruttererFase 3
Alder 18 til 70 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology & Hepatology Specialists, Inc.-Site nUmber: 8400139, Canton
- University Hospitals Cleveland Medical Center-Site Number: 8400073, Cleveland
- Ohio Gastroenterology Group Inc.-8400006, Columbus
- og 5 flere
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Ohio Gastroenterology Group Inc.-Site Number: 8400006, Columbus
- Medical Associates Research Group-Site Number: 8400063, Columbus
- OSU Wexner Medical Center-Site Number: 8400077, Columbus
- og 1 flere
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Cleveland Clinic - Cleveland /ID# 256453, Cleveland
RekruttererFase 3
Alder 2 til 17 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT05995353A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Cincinnati, Cincinnati
- Ohio Gastroenterology group, Inc., Columbus
- Great Lakes Gastroenterology Research, LLC, Mentor
- og 1 flere
RekruttererFase 4
Alder 18 til 70 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT07577843Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
- Cleveland Clinic, Cleveland
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 27. aug. 2026 · NCT07680283A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Childrens Medical Center, Dayton
RekruttererFase 3
Alder 2 til 17 · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05509777Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of Cincinnati, Cincinnati
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT07237516Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- UH Cleveland Medical Center /ID# 262188, Cleveland
RekruttererFase 3
Alder 2 til 17 · Alle kjønn · Oppdatert 24. jun. 2026 · NCT06332534A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Children's Clinic, Cleveland
- Cleveland Clinic, Cleveland
RekruttererFase 3
Alder 2 til 17 · Alle kjønn · Oppdatert 22. jun. 2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Cincinnati Children's Hospital Medical Center, Cincinnati
- UH/Rainbow Babies and Children's Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
RekruttererFase 4
Alder 6 til 17 · Alle kjønn · Oppdatert 27. mai 2026 · NCT05781152A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
RekruttererFase 3
Alder 2 og eldre · Alle kjønn · Oppdatert 7. mai 2026 · NCT05442567Precise Infliximab Exposure and Pharmacodynamic Control
- Cincinnati Children's Hospital, Cincinnati
- Cleveland Clinic Children's Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
RekruttererFase 2/3
Alder 6 til 22 · Alle kjønn · Oppdatert 5. mai 2026 · NCT05660746A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 3
Alder 2 til 17 · Alle kjønn · Oppdatert 5. mai 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- OSU Inflammatory Bowel Disease Center, Hilliard
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 27. apr. 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cincinnati
- Mirador Therapeutics Selected Site, Liberty Township
RekruttererFase 2
Alder 18 til 80 · Alle kjønn · Oppdatert 12. mar. 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Cleveland Clinic, Cleveland
RekruttererFase 1/2
Alder 18 til 65 · Alle kjønn · Oppdatert 10. des. 2025 · NCT06721962Evaluation of the SMART IBD App in Pediatric IBD
- Cincinnati Children's Hospital Medical Center, Cincinnati
Rekrutterer
Alder 13 til 17 · Alle kjønn · Oppdatert 21. nov. 2025 · NCT07195123Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
- Cleveland Clinic Foundation, Cleveland
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 12. nov. 2025 · NCT06670638Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.